Solid Biosciences (SLDB) EBITDA Margin (2022)

Solid Biosciences' (SLDB) quarterly EBITDA Margin came in at 407.89% in Q2 2022.

Solid Biosciences (SLDB) EBITDA Margin (2022) Analysis & Trends

Solid Biosciences has disclosed EBITDA Margin across 1 years of filings, most recently posting 407.89% for Q2 2022.

EBITDA Margin for Q2 2022 came in at 407.89%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was 1813.75% (down 40115.0% YoY), and the FY2022 annual result was 1315.2%, down 78470.0% from the prior year.
EBITDA Margin came in at 407.89% for Q2 2022 at Solid Biosciences.
In the past five years, EBITDA Margin ranged from a high of 407.89% in Q2 2022 to a low of 407.89% in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-6.43%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	38.10%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Solid Biosciences	789.54 Mn	408.86 Mn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2022	-407.89%